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Purpose: Dyslipidemia has been established as one of the most important modifiable risk factors for cardiovascular disease. Due to 
the higher prevalence of dyslipidemia in males, this study aimed to estimate the prevalence of dyslipidemia in Iranian urban men.
Materials and Methods: A screening program was conducted in 845 Iranian men 25 years of age and older in 2014. A health 
interview survey was conducted to evaluate the prevalence of self-reported dyslipidemia and to collect demographic data, as well 
as serum lipid profile screening by a reference laboratory. Lipoprotein levels was categorized based on the Adult Treatment Panel 
III criteria and the data were analyzed using the chi-square test and analysis of variance.
Results: The overall prevalence of dyslipidemia was 51.8%, and the prevalence of various forms of dyslipidemia was as follows: 
hypercholesterolemia (≥240 mg/dL), 11.4%; hyper-low-density lipoprotein cholesterol (≥160 mg/dL), 9.6%; hypertriglyceri-
demia (≥200 mg/dL), 25%; and hypo-high-density lipoprotein (HDL) cholesterol (＜40 mg/dL), 34.3%. With the exception of 
hypo-HDL, all forms of dyslipidemia were significantly less common in men over 65 years of age (p＜0.05).
Conclusions: The prevalence of hypo-HDL and hypertriglyceridemia was higher than expected in Iranian adult men, with half 
of men 25 years of age and older affected by at least one form of dyslipidemia. A large gap in primary and secondary care was 
observed, because nearly 80% of patients with dyslipidemia were unaware of their status. Urgent preventive programs and 
lifestyle changes are necessary to reduce the prevalence of cardiovascular risk factors.
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INTRODUCTION
　Cardiovascular disease (CVD) is the most prevalent 
cause of death among non-communicable diseases 
(NCDs) and disabilities worldwide, in both developed and 
developing countries [1-3]. Dyslipidemia has been estab-
pISSN: 2287-4208 / eISSN: 2287-4690
World J Mens Health 2015 December 33(3): 167-173
http://dx.doi.org/10.5534/wjmh.2015.33.3.167
168   World J Mens Health Vol. 33, No. 3, December 2015
lished as one of the most important modifiable risk factors 
for CVD [4], and patients with dyslipidemia are at a 31% 
to 46% higher risk for coronary artery disease [2]. Dyslipi-
demia is a condition in which lipid metabolism is dis-
rupted, leading to an abnormal amount of lipids in the 
blood [5]. It plays a major role in the expansion and pro-
gression of atherosclerosis [6,7]. Moreover, lipid abnor-
malities are recognized as a major risk factor for early cor-
onary artery disease in particular [1]. A 30-year cohort 
study showed that each increase of 10 mg/dL in total cho-
lesterol (TC) was associated with increases of 5% and 9% 
in total mortality and cardiovascular mortality, re-
spectively [7].
　The worldwide prevalence of dyslipidemia is increasing, 
and the risk of mixed forms of dyslipidemia is growing due 
to the increased prevalence of other metabolic diseases, 
such as visceral adiposity, metabolic syndrome/insulin re-
sistance, and diabetes mellitus [4,8-10]. These changes 
have occurred due to urbanization, changes in diet pat-
terns, obesity, reduced physical activity, and other con-
sequences of lifestyle changes [4]. The typical forms of dys-
lipidemia include elevated TC, elevated triglycerides (TG), 
elevated low-density lipoprotein (LDL) cholesterol, and re-
duced high-density lipoprotein (HDL) cholesterol [7].
　The relationship between dyslipidemia and other risk 
factors for NCDs such as hypertension, diabetes mellitus, 
obesity, and overweight has been previously evaluated in 
studies and it is established a high prevalence of diabetes 
mellitus, obesity, hypertension, and overweight in adults 
[8-12]. A recent study showed overweight and obesity to 
be the most significant factors contributing to the burden 
of NCDs [3]. Moreover, overweight and obesity have been 
reported to have an effect on dyslipidemia [5]. 
　An increasing trend in the prevalence of dyslipidemia 
has been observed in adults in many countries, including 
Korea [7], Kuwait [5], and other Persian Gulf countries and 
neighbors of Iran [3,4,10,13]. Nevertheless, the preva-
lence of undiagnosed dyslipidemia in the adult male pop-
ulation is unclear, and many men are unaware of their lip-
id profile, leading to a high prevalence of patients with un-
treated lipid abnormalities [2,14]. In addition, the preva-
lence of dyslipidemia is higher in males than females 
[1,11], and higher levels of HDL and lower ratios of TC to 
HDL have been reported in females [15]. This study aimed 
to estimate the prevalence of dyslipidemia in Iranian ur-
ban men 25 years of age and older in order to design ap-
propriate health interventions at the primary and secon-
dary levels to reduce CVD events.
MATERIALS AND METHODS
1. Setting and subjects
　The study setting was Qom, a metropolis in central Iran. 
A screening program was conducted in Iranian men 25 
years of age and older in 2014. Subjects were selected by 
two-stage sampling. First, proportional stratified random 
sampling was used to establish the proportion of each 
district. Second, systematic random sampling used to se-
lect eligible subjects in each stratum. The study subjects 
comprised a random sample of men at least 24 years of age 
living in Qom. 
2. Measurements
　The subjects included 845 urban adult men. A health in-
terview survey was administered to all subjects in order to 
evaluate self-reported dyslipidemia and to collect demo-
graphic data, and then all subjects were referred to a refer-
ence laboratory for lipoprotein screening tests. According 
to the program protocol, all men between 25 to 65 years 
old were invited to participate in the screening and under-
go anthropometric measurements and a measurement of 
their serum lipid profile. In the current study, all men 25 
years of age and older were assessed. The serum lipid pro-
file included TC, HDL, LDL, very low-density lipoprotein 
(VLDL), and TG. The lipoprotein screening tests were per-
formed after the subjects had fasted for at least eight hours. 
The data were gathered in two stages. First, an interview 
was conducted, in which questions about demographic 
characteristics, including age, marital, and insurance sta-
tus, the number of children, and self-reported NCD status 
were asked. Second, the results of the laboratory tests 
were added to the demographic data. The study partic-
ipants were made aware of the benefits and harms of the 
study and, because the laboratory tests were free, all par-
ticipants provided informed consent. In addition, the 
study protocol was approved by the ethical committee of 
the Qom University of Medical Sciences. 
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Table 1. Dyslipidemia prevalence in the subjects of our study based on laboratory results and Adult Treatment Panel (ATP)
III criteria
Fasting lipoprotein levels based on ATP III criteria Level (mg/dL) Frequency (n) Valid (%) Cumulative (%)
Total cholesterol Desirable ＜200 546 66.9 66.9
Borderline high 200∼240 177 21.7 88.6
High ＞240 93 11.4 100.0
LDL Optimal ＜100 316 40.0 40.0
Above optimal 100∼129 238 30.1 70.1
Borderline high 130∼159 160 20.3 90.4
High 160∼190 54 6.8 97.2
Very high ≥190 22 2.8 100.0
HDL Low ＜40 280 34.3 34.3
Normal 40∼59 472 57.8 92.2
High ≥60 64 7.8 100.0
TG Desirable ＜150 474 58.1 58.1
Borderline high 150∼199 138 16.9 75.0
High 200∼500 189 23.2 98.2
Very high ≥500 15 1.8 100.0
VLDL Low ＜5 5 0.7 0.7
Normal 5∼40 531 73.4 74.1
High ＞40 187 25.9 100.0
LDL/HDL Favorable ≤4.5 699 93.2 93.2
Unfavorable ≥4.5 51 6.8 100.0
LDL: low-density lipoprotein, HDL: high-density lipoprotein, TG: triglycerides, VLDL: very low-density lipoprotein.
3. Statistical analysis
　After data collection, the results of the laboratory tests 
were categorized based on the Adult Treatment Panel III 
criteria [16]. LDL cholesterol values were calculated 
based on TC, TG, and HDL. In addition, VLDL was esti-
mated as one fifth of the total lipids in a given blood sam-
ple [16,17]. In our study, dyslipidemia was defined as of 
the presence of hypercholesterolemia (≥240 mg/dL), hy-
po-HDL (＜40 mg/dL), hyper-LDL (≥160 mg/dL), or hy-
per-TG (≥200 mg/dL), according to the Adult Treatment 
Panel III criteria presented in Table 1 [7]. Since the target 
population of the screening program was men between 25 
and 65 years of age, the study subjects were categorized as 
between 25 and 40 years of age, 40 to 65 years of age, and 
more than 65 years of age. These groups contained 
30.3%, 32.8%, and 36.9% of the study sample, respec-
tively. Data were analyzed using the chi-square test and 
analysis of variance in PASW Statistics ver. 18 (IBM Co., 
Armonk, NY, USA). 
RESULTS
　The mean age of participants was 45.3±18.8 years old, 
70.7% lived with their spouse, and 98% reported having 
health insurance. The self-reported prevalence of dyslipi-
demia and high blood pressure was 16.9% and 19.4%, 
respectively. In contrast, the overall prevalence of labo-
ratory-confirmed dyslipidemia (i.e., the presence of hyper-
cholesterolemia, hypo-HDL, hyper-LDL, or hyper-TG) was 
51.8%. As shown in Table 1, the prevalence of desirable 
TC was 66.9% and the prevalence of high TC was 11.4%. 
Hyper-LDL and hypertriglyceridemia were present in 
9.6% and 25% of participants, respectively. The preva-
lence of high VLDL was 25.9%, and the prevalence of nor-
mal HDL was 57.8%, whereas 34.3% of participants were 
affected by hypo-HDL. Finally, the ratio of LDL to HDL 
was unfavorable in 6.8% of subjects. 
　According to the results presented in Table 2, 75.3% of 
the subjects affected by hypercholesterolemia were not 
aware of their condition. Moreover, 79.6% and 81.8% of 
the subjects with high and very high levels of LDL, re-
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25∼40 (n=332) 40∼65 (n=180) ＞65 (n=300)
Total cholesterol 187.3±38.5 191.1±45.9 183.9±43.6 0.196
LDL 111.4±39.1 113.8±37.7 113.2±37.3 0.755
HDL 46.1±18.9 44±10.2 46.3±10.1 0.189
TG 177.1±98.1 182±129.1 137.7±69.2 ＞0.001
VLDL 34.3±16.6 34.2±17.4 27.7±13.8 ＞0.001
LDL/HDL 2.62±1.1 3.33±7.68 2.53±1.16 0.073
LDL: low-density lipoprotein, HDL: high-density lipoprotein, TG: triglycerides, VLDL: very low-density lipoprotein.
Table 2. The prevalence of unknown dyslipidemia in study subjects based on a comparison of self-reported vs. laboratory
results
Fasting lipoprotein level Known Unknown p-value
Total cholesterol Desirable 86 (15.8) 460 (84.2) 0.10
Borderline high 29 (16.4) 148 (83.6)
High 23 (24.7) 70 (75.3)
LDL Optimal 54 (17.1) 262 (82.9) 0.584
Above optimal 35 (14.7) 203 (85.3)
Borderline high 28 (17.5) 132 (82.5)
High 11 (20.4) 43 (79.6)
Very high 4 (18.2) 18 (81.8)
HDL Low 53 (18.9) 227 (81.1) 0.515
Normal 74 (15.7) 398 (84.3)
High 11 (17.2) 53 (82.8)
TG Desirable 70 (14.8) 404 (85.2) 0.239
Borderline high 27 (19.6) 111 (80.4)
High 37 (19.6) 152 (80.4)
Very high 4 (26.7) 11 (73.3)
VLDL Low 0 (0) 5 (100) 0.417
Normal 91 (17.1) 440 (82.9)
High 37 (19.8) 150 (80.2)
LDL/HDL Favorable 116 (16.6) 583 (83.4) 0.230
Unfavorable 11 (21.6) 40 (78.4)
Values are presented as number (%).
LDL: low-density lipoprotein, HDL: high-density lipoprotein, TG: triglycerides, VLDL: very low-density lipoprotein.
spectively, had not been diagnosed. Likewise, 80.4% and 
73.3% of the subjects with high and very high TG, re-
spectively, had not been diagnosed. Of the subjects with 
low HDL, 81.1% had not been diagnosed, as was the case 
for 80.2% of subjects with high VLDL and 78.4% of sub-
jects with an unfavorable LDL/HDL ratio.
　As shown in Table 3, the mean of all lipoprotein levels 
was lower in men over 65 years of age, with the exception 
of HDL. Moreover, analysis of variance demonstrated a 
significant difference in the mean TG and VLDL values be-
tween men older and younger than 65 years (p＜0.05). In 
addition, lipid profiles were compared across three differ-
ent age groups. According to results presented in Table 4, 
all lipid parameters except HDL were different to a statisti-
cally significant extent among men 25 to 40 years of age, 
40 to 65 years of age, and over 65 years of age. Moreover, 
dyslipidemia was not found to increase with age. The 
highest prevalence of dyslipidemia was observed in sub-
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25∼40 (n=332) 40∼65 (n=180) ＞65 (n=300)
Total cholesterol Desirable 177 (71.7) 157 (58.6) 212 (70.4) 0.003
Borderline high 51 (20.6) 66 (24.6) 60 (19.9)
High 19 (7.7) 45 (16.8) 29 (9.6)
LDL Optimal 114 (47.7) 90 (34.9) 112 (38.2) 0.020
Above optimal 69 (28.9) 75 (29.1) 94 (32.1)
Borderline high 42 (17.6) 58 (22.5) 60 (20.5)
High or very high 14 (5.8) 35 (13.6) 27 (9.2)
HDL Low 85 (34.4) 102 (38.1) 93 (30.9) 0.187
Normal 145 (58.7) 150 (56.0) 177 (58.8)
High 17 (6.9) 16 (6.0) 31 (10.3)
TG Desirable 131 (53.0) 132 (49.3) 211 (70.1) ＜0.001
Borderline high 43 (31.2) 46 (33.3) 49 (35.5)
High or very high 73 (29.5) 90 (33.6) 41 (13.6)
VLDL Low 3 (1.3) 0 (0) 2 (0.8) ＜0.001
Normal 156 (68.1) 166 (66.4) 209 (85.7)
High 70 (30.6) 84 (33.6) 33 (13.5)
LDL/HDL Favorable 229 (96.2) 229 (90.2) 241 (93.4) 0.028
Unfavorable 9 (3.8) 25 (9.8) 17 (6.6)
Values are presented as number (%).
LDL: low-density lipoprotein, HDL: high-density lipoprotein, TG: triglycerides, VLDL: very low-density lipoprotein.
jects between 40 and 65 years of age. Desirable levels of 
all lipoproteins except HDL were more common in partic-
ipants more than 65 years of age than in subjects between 
40 to 65 years of age (p＜0.05). 
DISCUSSION
　The overall prevalence of dyslipidemia (i.e., the pres-
ence of hypercholesterolemia, hypo-HDL, hyper-LDL, or 
hyper-TG) was 51.8%. This rate has been found to vary 
among studies conducted in a range of countries. Similar 
results were reported in a 2005 study of Korean adults that 
found the dyslipidemia prevalence in the adult population 
over the age of 30 years to be nearly 50% [7]. However, in 
a study of Turkish adults, 78.7% of men and 80.4% of 
women were diagnosed with at least one lipid abnormal-
ity [4]. Moreover, 75.7% of Jordanian adults aged 25 years 
and older were found to be affected by dyslipidemia [11]. 
Therefore, the dyslipidemia prevalence in Jordanian and 
Turkish adults has been reported to be higher than the 
prevalence observed in our study among Iranian subjects. 
In contrast, a lower prevalence of dyslipidemia has been 
identified in Pakistan (32.7% of adults) [18] and Canada 
(14.0% of adults) [2]. Therefore, different lifestyles, access 
to care, and variations in race or ethnicity may influence 
the prevalence of hyperlipidemia. Other studies have 
found inequities in health care utilization according to 
demographic factors [19-24].
　The self-reported prevalence of dyslipidemia was 
16.9%, whereas laboratory results found a prevalence of 
51.8%. Therefore, a large proportion of patients with dys-
lipidemia are unaware of their lipid profile and are not tak-
ing measures to treat or control their lipid levels. We found 
that nearly 80% of people affected by hypercholesterolemia, 
hyper-LDL, hypo-HDL, and unfavorable HDL to LDL ra-
tios were unaware of this. The overall prevalence of hyper-
cholesterolemia was 11.4% and that of hypo-HDL was 
34.3%. Sawant et al [1] studied Indian adults and found 
that the prevalence of hypercholesterolemia and hy-
po-HDL in men was 38.7% and 64.2%, respectively. In 
that study, the prevalence of hyper-LDL and hypertrigly-
ceridemia was 9.6% and 25%, respectively. In a study of 
Jordanian adults aged 25 years and older 48.8% had high 
TC levels, 40.7% had high LDL, 40.1% had low HDL, and 
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43.6% had high TG levels [11]. A nationwide study of the 
Turkish population, with participants ranging from 20 to 
83 years of age, found that 43% had high TC, 41.5% had 
low HDL, 36.2% had high LDL, and 35.7% had high TG 
[4]. 
　According to the results of the current study, the most 
prevalent forms of dyslipidemia were hypo-HDL, hyper- 
VLDL, and hypertriglyceridemia. Another Iranian study 
[25] conducted in northwestern Iranian urban adults over 
20 years old found a prevalence of hypo-HDL of 63% in 
men. In addition, hypertriglyceridemia was found in 40.6% 
of subjects, making it the second most prevalent abnor-
mality, and hypercholesterolemia was observed in 35.4% 
of subjects. Therefore, the dyslipidemia prevalence re-
ported in our study is concordant with those reported by 
other studies. The most common forms of dyslipidemia in 
Korean adults were found to be hypo-HDL and hyper-
triglyceridemia [7]. Identically to our results, hypo-HDL 
and hypertriglyceridemia were found to be the most prev-
alent types of dyslipidemia in Mexican adults [6]. 
　Our results showed the highest prevalence of dyslipide-
mia in men between 40 and 65 years of age. Moreover, the 
mean values of all lipid parameters were lower in men 
over 65 years old, with the exception of HDL. Similarly, a 
Turkish study showed that the prevalence of high TC, LDL, 
and TG increased with age, with the highest prevalence in 
the 46- to 65-year-old age group [4]. Recent studies have 
found age to be associated with dyslipidemia, especially 
high TG, high LDL, and high TC [1,7,11]. In one study, hy-
percholesterolemia and hypertriglyceridemia were found 
to be more prevalent in the 31- to 40-year-old age group 
than in subjects younger than 31 years old [1]. Analogously, 
a study in Taiwan found an overall prevalence of hyper-
triglyceridemia of 13.4%, decreasing to 12.3% in men 
over 45 years of age, whereas the hypercholesterolemia 
prevalence was 2.4% higher in men over 45 years of age 
than in young adult men [15]. In the Nutrition and Health 
Survey in Taiwan, Chang et al [15] found that cholesterol 
levels were lower in men over 45 years of age than in other 
age groups, whereas TG levels were higher above the age 
of 45 years. 
　Other studies have shown inhabitants of metropolitan 
cities to have higher levels of serum cholesterol than those 
who live in other areas [15]. Qom is one of the major cities 
of Iran, and urbanization has affected the lifestyle of the 
population. Therefore, risk factors for NCDs are common 
and are often undiagnosed in the urban population. In our 
study, in addition to the high prevalence of the most com-
mon forms of dyslipidemia, the prevalence of high VLDL 
was 25.9% and the LDL to HDL ratio was unfavorable in 
6.8% of subjects. In a Canadian cohort study [2], 63.2% of 
patients with dyslipidemia were untreated. Of those treat-
ed, dyslipidemia was not adequately controlled in 47.2% 
[2]. Although our study estimated the prevalence of dysli-
pidemia in different age groups and the prevalence of un-
diagnosed dyslipidemia, it did not determine how many 
patients were not treated or were inadequately treated. 
Moreover, dyslipidemia prevalence was not reported ac-
cording to demographic characteristics such as body mass 
index and smoking, making further studies necessary.
CONCLUSIONS
　The prevalence of dyslipidemia, especially hypo-HDL 
and hypertriglyceridemia, was higher than expected in 
Iranian adult men. More than half of men 25 years of age 
and older were affected by at least one abnormality in their 
lipid profile. In addition, nearly 80% of patients with dysli-
pidemia were unaware of having dyslipidemia, suggesting 
a gap in primary and secondary care. Therefore, urgent 
preventive programs and lifestyle changes in the form of 
community-based intervention strategies are necessary to 
prevent and manage cardiovascular risk factors. 
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